Quest Diagnostics (NYSE:DGX) CAO Michael Deppe Sells 11,776 Shares of Stock

Quest Diagnostics Incorporated (NYSE:DGX – Get Free Report) CAO Michael Deppe sold 11,776 shares of the firm’s stock in a transaction dated Friday, November 13th. The shares were sold at an average price of $260.17, for a total transaction of $3,063,761.92. Following the completion of the sale, the chief accounting officer owned 35,203 shares of the company’s stock, valued at $9,158,764.51. The trade was a 25.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Quest Diagnostics Trading Up 0.8%

DGX stock traded up $2.07 during midday trading on Monday, reaching $261.67. The company’s stock had a trading volume of 734,851 shares, compared to its average volume of 975,934. Quest Diagnostics Incorporated has a 52 week low of $171.18 and a 52 week high of $263.19. The business’s 50-day simple moving average is $241.23 and its 200-day simple moving average is $215.58. The company has a quick ratio of 1.58, a current ratio of 1.70 and a debt-to-equity ratio of 0.70. The stock has a market cap of $28.79 billion, a PE ratio of 26.06, a price-to-earnings-growth ratio of 2.32 and a beta of 0.54.

Quest Diagnostics (NYSE:DGX – Get Free Report) last posted its earnings results on Thursday, October 22nd. The medical research company reported $3.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.87 by $0.13. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. The business had revenue of $3.10 billion during the quarter, compared to analysts’ expectations of $3.05 billion. During the same period in the prior year, the business earned $2.60 EPS. Quest Diagnostics’s revenue for the quarter was up 10.0% compared to the same quarter last year. As a group, sell-side analysts expect that Quest Diagnostics Incorporated will post 11.29 EPS for the current year.

Quest Diagnostics Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 27th. Shareholders of record on Tuesday, January 12th will be issued a $0.86 dividend. The ex-dividend date of this dividend is Tuesday, January 12th. This represents a $3.44 annualized dividend and a yield of 1.3%. Quest Diagnostics’s payout ratio is currently 34.26%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on DGX. Weiss Ratings upgraded shares of Quest Diagnostics from a “buy (a)” rating to a “buy (a+)” rating in a report on Wednesday, October 21st. JPMorgan Chase & Co. upped their target price on Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a report on Tuesday, July 28th. Jefferies Financial Group reissued a “buy” rating and issued a $245.00 price objective on shares of Quest Diagnostics in a report on Thursday, July 23rd. Mizuho upped their target price on shares of Quest Diagnostics from $235.00 to $260.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Finally, Barclays upped their price objective on Quest Diagnostics from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $248.70.

Get Our Latest Report on DGX

Institutional Investors Weigh In On Quest Diagnostics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Choreo LLC boosted its stake in shares of Quest Diagnostics by 2.4% during the 3rd quarter. Choreo LLC now owns 2,215 shares of the medical research company’s stock worth $516,000 after acquiring an additional 52 shares in the last quarter. Utah Retirement Systems grew its holdings in shares of Quest Diagnostics by 0.3% during the third quarter. Utah Retirement Systems now owns 16,818 shares of the medical research company’s stock worth $3,920,000 after buying an additional 53 shares in the last quarter. Kingswood Wealth Advisors LLC lifted its stake in shares of Quest Diagnostics by 1.4% during the 3rd quarter. Kingswood Wealth Advisors LLC now owns 3,878 shares of the medical research company’s stock worth $904,000 after purchasing an additional 55 shares during the period. Concurrent Investment Advisors LLC boosted its stake in Quest Diagnostics by 1.2% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 5,183 shares of the medical research company’s stock worth $1,099,000 after buying an additional 62 shares during the last quarter. Finally, Allworth Financial LP grew its holdings in Quest Diagnostics by 3.9% in the third quarter. Allworth Financial LP now owns 1,741 shares of the medical research company’s stock valued at $369,000 after purchasing an additional 66 shares during the period. 88.06% of the stock is owned by hedge funds and other institutional investors.

About Quest Diagnostics

(Get Free Report)

Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.

Featured Stories

Insider Buying and Selling by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.